Details of the Drug

General Information of Drug (ID: DM51OQW)

• Drug Name: Oxprenolol
• Synonyms: Coretal; Koretal; Laracor; Osprenololo; Oxprenololum; Tevacor; Trasacor; Trasicor; Osprenololo [DCIT]; Slow Trasicor; Trasicor 80; Captol (TN); Corbeton (TN); Coretal (TN); Dl-Alprenolol; Dl-Oxprenolol; Laracor (TN); Oxprenolol (INN); Oxprenolol (TN); Oxprenolol [INN:BAN]; Oxprenololum [INN-Latin]; Slow-pren; Tevacor (TN);Trasacor (TN); Trasicor (TN); Trasidex (TN); Trasitensin (TN); Slow-Pren (TN); Slow-Trasicor (TN); Coretal (*hydrochloride*); Laracor (*hydrochloride*); Oxprenolol Ba 39089 (*hydrochloride*); Trasacor (*hydrochloride*); Trasicor (*hydrochloride*); Slow-Pren (*hydrochloride*); (+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-Oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(2-(2-propenyloxy)phenoxy)-2-propanol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol; 1-[(1-Methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-2-propanol; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol

Indication

Disease Entry	ICD 11	Status	REF
Anxiety	N.A.	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Long QT syndrome	BC65.0	Approved	[1]
Malignant essential hypertension	BA00	Approved	[1]

• Therapeutic Class: Antihypertensive Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  C07AA02: Oxprenolol
  C07AA: Beta blocking agents, non-selective
  C07A: BETA BLOCKING AGENTS
  C07: BETA BLOCKING AGENTS
  C: CARDIOVASCULAR SYSTEM
  C07AA02: Oxprenolol
  C07AA: Beta blocking agents, non-selective
  C07A: BETA BLOCKING AGENTS
  C07: BETA BLOCKING AGENTS
  C: CARDIOVASCULAR SYSTEM
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 265.35
  Logarithm of the Partition Coefficient (xlogp); 2.1
  Rotatable Bond Count (rotbonds); 9
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: The bioavailability of drug is 20-70% []
  Clearance: The drug present in the plasma can be removed from the body at the rate of 7.7 mL/min/kg [4]
  Elimination: 3% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1 - 2 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.1442 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.19% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.72 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 30.86 mg/mL [3]
• Chemical Identifiers:
  Formula: C15H23NO3
  IUPAC Name: 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol
  Canonical SMILES: CC(C)NCC(COC1=CC=CC=C1OCC=C)O
  InChI: InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
  InChIKey: CEMAWMOMDPGJMB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4631
  ChEBI ID: CHEBI:91704
  CAS Number: 6452-71-7
  UNII: 519MXN9YZR
  DrugBank ID: DB01580
  TTD ID: D0X2MB
  VARIDT ID: DR00697
  INTEDE ID: DR1216
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Renin (REN)	OT52GZR2	RENI_HUMAN	Gene/Protein Processing	[8]
Vasopressin-neurophysin 2-copeptin (AVP)	OTAVZ76K	NEU2_HUMAN	Gene/Protein Processing	[9]

References

• [1] Oxprenolol FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7255).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [7] Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
• [8] Mediation of renin release in essential hypertension by alpha-adrenoreceptors. J Cardiovasc Pharmacol. 1981 Nov-Dec;3(6):1153-61. doi: 10.1097/00005344-198111000-00001.
• [9] Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension. Acta Med Scand. 1984;215(2):165-72. doi: 10.1111/j.0954-6820.1984.tb04988.x.